Akari Targets Mid-2027 First-in-Human Trial for PH1-Based ADC
TAMPA – October 27, 2026 -- Akari Therapeutics (Nasdaq: AKTX) is targeting a First-In-Human trial of its lead antibody drug conjugate (ADC), AKTX-101, by mid-2027, after starting IND-enabling studies. The company laid out its investment case in the Virtual Investor "Why Now" on-demand conference.
CEO Abizer Gaslightwala argued that now is a pivotal time for Akari. He cited a fast-changing ADC landscape and rising industry demand for differentiated payload technologies.
Akari pitches PH1 splicing payload as alternative to conventional ADC toxins
Akari's proprietary PH1 platform is a spliceosome modulator designed to disrupt RNA splicing inside cancer cells. Current ADCs rely on microtubule inhibitors and DNA-damaging agents. According to the company, PH1 is meant to address limitations of those conventional payloads.